David Reardon, MD, discusses the interim results and toxicity with INO-5401 and INO-9012 delivered intramuscularly with electroporation in combination with cemiplimab in patients with newly diagnosed glioblastoma.
David Reardon, MD, clinical director for the Center for Neuro-Oncology and institute physician at the Dana-Farber Cancer Institute, and professor of medicine at Harvard Medical School, discusses the interim results and toxicity with INO-5401 and INO-9012 delivered intramuscularly with electroporation in combination with cemiplimab (Libtayo) in patients with newly diagnosed glioblastoma.
According to Reardon, these agents were well tolerated and there were no significant adverse effects (AEs) associated with the vaccine. Cemiplimab showed the usual spectrum of AEs that are usually associated with PD-1 inhibitor therapies and there were no unexpected or new toxicities in the context of treating patients with glioblastoma.
There were 52 patients treated on the trial; 32 in cohort A, which was the O6-methylguanine-DNA methyltransferase (MGMT) unmethylated group, and 20 in cohort B, which was MGMT methylated. All of these patients had a reassuring safety profile, Reardon says.
It is too early to assess the efficacy of the regimen in these patients, but initial results showed encouraging progression-free survival results at 6 months and overall survival at 12 months. They were both higher than what would be expected at the time of the interim analysis for patients with newly diagnosed disease, according to Reardon. It is still too early to draw conclusions with these data.
<< View more resources and information regarding brain cancer
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More